Clinical trial · Observational
Changes of Muramyl Dipeptide in Intestinal and Extra-intestinal Diseases
A Bacterial Bi-functional Peptidoglycan Hydrolase Sheds NOD2 Ligands to Regulate Gut Homeostasis
NCT04924686CI-TRIAL-00052264unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nucleotide-binding oligomerization domain 2 (Nod2) signaling is critical for human health.To figure out the clinical relevance of NOD2 ligands, the investigators plan to evaluate the change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC, atherosclerotic cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ).
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Atherosclerotic Cardiovascular Disease | — | UNRESOLVED | — |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Inflammatory Bowel Disease | — | UNRESOLVED | — |
| Type2 Diabetes Mellitus | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observational studies, no intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- label
- Crohn's disease
- description
- The fecal and plasma were collected
- interventionNames
- Other: Observational studies, no intervention
- label
- Ulcerative colitis
- description
- The fecal and plasma were collected
- interventionNames
- Other: Observational studies, no intervention
- label
- Diabetes mellitus, type 2
- description
- The fecal and plasma were collected
- interventionNames
- Other: Observational studies, no intervention
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Males or females at least 18-70 years old. 2. Patient able to give informed consent. 3. Patient with biopsy-proven CRC 4. Patient with biopsy-proven Crohn's disease (CD) or ulcerative colitis(UC), in the active phase. 5. patients with clinical diagnosed DM2 6. patients with ACVD:coronary angiography more than 50% stenosis in single or multiple vessels. 7. The age- and sex- matched health controls for each patient. Exclusion Criteria: 1.Use antibiotics or probiotics within the last 2 weeks.
References
Publications (1)
- BACKGROUNDPhilpott DJ, Sorbara MT, Robertson SJ, Croitoru K, Girardin SE. NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol. 2014 Jan;14(1):9-23. doi: 10.1038/nri3565. Epub 2013 Dec 13. PMID 24336102